San Francisco,9 October
2018: The global liquid biopsy market size is expected to reach USD 5.96 billion by 2030,
according to a new report by Grand View Research, Inc., exhibiting a CAGR of
13.4% during the forecast period. Enhanced view of tumor provided by liquid
biopsy technology is estimated to augment the market in coming years.
While tissue biopsies have been standard
for cancer diagnosis for past several year, their highly invasive nature and
frequently associated complications have been major concerns. Moreover, these
biopsies lead to high expenditure being incurred by patients. Liquid biopsies,
on the other hand, offer a less invasive methodology along with high
effectiveness. Thus, there are a number of key private organizations involved
in rigorous R&D activities for liquid biopsy test development and it is
only a matter of time before these procedures grow in prominence in diagnostic
paraphernalia of oncologists and pathologists.
Access Research Report
of Liquid Biopsy Market@ www.grandviewresearch.com/industry-analysis/liquid-biopsy-market
Further key findings from the report suggest:
· Technological developments such as electric
field induced release and measurement (EFIRM)- Liquid Biopsy (eLB), which
provides detection that can assist clinical treatment decisions for most common
subtype of cancers are expected to drive the uptake of saliva based sampling
over the forecast period
· Currently, clinical use of isolation and
detection technology is limited to CTC quantitation but the number of CTCs is
found to hold significant correlation with disease severity. This is, thus,
estimated to augment the market over the coming years
· Rising awareness regarding advantages of
multiple gene analysis along with the help of NGS is anticipated to support the
growth of the market
· Organizations such as American Society of
Clinical Oncology (ASCO) are engaged in supporting implementation of liquid
biopsy, which in turn is likely to spur the growth of the market
· Intensifying competition between biotech
companies and increasing investments by government in healthcare institutes
will lead to development of more sophisticated tests
· Companies engaged in R&D and
commercialization of these products include Pathway Genomics; Natera Inc.; Epic
Sciences; Illumina; Foundation Medicine; Roche; LabCorp; and Sequenom
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/biotechnology
Grand View Research has segmented the
global liquid biopsy marketon the basis of application, sample type, biomarker,
technology, and region:
Liquid Biopsy Application Outlook (Revenue, USD Million,
2013 - 2030)
·
Therapy Selection for Metastatic Breast
Cancer (MBS)
·
Therapy Selection for Other Metastatic
Cancer
·
Molecular Health Monitoring
Liquid Biopsy Sample Type Outlook (Revenue, USD Million,
2013 - 2030)
·
Blood Sample based
·
Urine Sample based
·
Other Bio Fluids (Tissue fluids and Saliva)
based
Liquid Biopsy Biomarker Outlook (Revenue, USD Million,
2013 - 2030)
·
Circulating Tumor Cells (CTC)
·
Circulating Tumor DNA (ctDNA)
·
Exosomes
Liquid Biopsy Technology Outlook (Revenue, USD Million,
2013 - 2030)
·
Multi-gene-parallel Analysis (NGS)
·
Single Gene Analysis (PCR Microarrays)
Liquid Biopsy Regional Outlook (Revenue, USD Million,
2013 - 2030)
·
North America
o
U.S.
o
Canada
·
Europe
o
Germany
o
U.K.
·
Asia Pacific
o
China
o
Japan
·
Latin America
o
Brazil
·
MEA
o South Africa
Access Press Release of
Liquid Biopsy Market@ www.grandviewresearch.com/press-release/liquid-biopsy-market
About
Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
